# Gastrointestinal Tolerability, Biliary Risk, and Retinopathy

> Safety and Side Effect Notes for Semaglutide New Mexico — Examine semaglutide New Mexico safety findings on nausea, cholelithiasis, SUSTAIN-6 diabetic retinopathy signals, unconfirmed cancer signals, and half-life.

**Part Four · Adverse Events, Warnings & Half-Life**

What the 2021 safety review and human outcome trials report on transient nausea, biliary disease, diabetic retinopathy complications in SUSTAIN-6, unconfirmed cancer signals, and an elimination half-life of approximately 1 week (~5 weeks in circulation after the last dose).

## Key Safety and Pharmacokinetic Takeaways

- Gastrointestinal events across 0.5-2.4 mg doses are mostly mild-to-moderate and transient, with nausea affecting roughly one-third of patients.
- The 2021 safety review reports an increased risk of biliary disease, specifically cholelithiasis.
- Pancreatic and thyroid-cancer signals remain unconfirmed because definitive conclusions cannot yet be drawn owing to low incidence.
- With an elimination half-life of approximately 1 week, semaglutide remains in circulation for approximately 5 weeks after the last dose.

## Nausea Incidence and Cholelithiasis Across 0.5 to 2.4 mg

Clinical safety evaluations of oral and subcutaneous semaglutide center on transient gastrointestinal symptoms, biliary disease, and low-incidence cancer surveillance, as synthesized in the 2021 [comprehensive safety review by Smits and Van Raalte](https://pubmed.ncbi.nlm.nih.gov/34305810/) in Frontiers in Endocrinology. Across therapeutic doses of 0.5-2.4 mg subcutaneous and oral, the review concludes that semaglutide has an overall favorable risk/benefit profile in type 2 diabetes, with mostly mild-to-moderate transient gastrointestinal effects and nausea in roughly one-third of patients.

Beyond transient gastrointestinal effects, the 2021 safety review reported an increased risk of biliary disease, specifically cholelithiasis. Meanwhile, for pancreatic and thyroid-cancer signals, definitive conclusions cannot yet be drawn owing to low incidence.

Pharmacokinetically, the 2024 [StatPearls drug monograph](https://www.ncbi.nlm.nih.gov/books/NBK603723/) states that both oral and subcutaneous semaglutide have an elimination half-life of approximately 1 week and remain in circulation for approximately 5 weeks after the last dose.

## Why SUSTAIN-6 Flagged Diabetic Retinopathy Complications (HR 1.76)

While [SUSTAIN-6 in type 2 diabetes](https://pubmed.ncbi.nlm.nih.gov/27633186/) (n=3,297) demonstrated a lower rate of major cardiovascular events with once-weekly 0.5 mg or 1.0 mg semaglutide (HR 0.74; 95% CI 0.58-0.95), rates of diabetic-retinopathy complications were higher in the semaglutide group (HR 1.76; 95% CI 1.11-2.78; P=0.02).

In the 2021 [Endocrinology safety review](https://pubmed.ncbi.nlm.nih.gov/34305810/), Smits and Van Raalte note that retinopathy monitoring is advised with rapid glycemic correction.

| Finding or Signal | Evidence Source | Magnitude or Clinical Detail |
| --- | --- | --- |
| Nausea and GI disturbances | Smits & Van Raalte safety review (2021) · 0.5-2.4 mg | Mostly mild-to-moderate and transient; nausea affects roughly one-third of patients |
| Diabetic retinopathy complications | SUSTAIN-6 trial (2016, n = 3,297) & 2021 safety review | Higher rates in SUSTAIN-6 (HR 1.76; 95% CI 1.11-2.78; P = 0.02); the 2021 review notes retinopathy monitoring is advised with rapid glycemic correction |
| Biliary disease (cholelithiasis) | Smits & Van Raalte safety review (2021) | Increased risk of biliary disease, specifically cholelithiasis |
| Elimination half-life and circulation | StatPearls monograph (2024) | Elimination half-life ~1 week; remains in circulation ~5 weeks after the last dose |

![Eye specialist holding a cobalt-rimmed condensing lens beside an optical slit-lamp instrument in consultation room](images/ophthalmic-slit-lamp-exam.webp)

*In SUSTAIN-6 (2016), rates of diabetic-retinopathy complications were higher with semaglutide (HR 1.76; 95% CI 1.11-2.78; P = 0.02), and the 2021 safety review by Smits and Van Raalte states that retinopathy monitoring is advised with rapid glycemic correction.*

---

On Semaglutide New Mexico, I share my own notes on published research for educational reading only, offering no medical advice, clinical care, or treatment instructions.